v3 Template
T

Tallac Therapeutics, Inc.

Biopharmaceutical ~380 employees
Founded
--
Employees (Est.)
~380
19 leaders known
Total Funding
$15.0M
Funding Rounds
1
Last Funding
2023-08-02

About Tallac Therapeutics, Inc.

Tallac Therapeutics™ is a privately held biopharmaceutical company focused on harnessing innate and adaptive immunity to fight cancer through the development of antibody drug conjugates (ADCs). Their mission is to deliver innovative therapies that trigger immune activation within the tumor microenvironment.

Products & Services

Toll-like Receptor Agonist Antibody Conjugates (TRAAC):A novel class of ADCs that systemically deliver potent Toll-like receptor (TLR9) agonists like T-CpG to activate immunity in the tumor microenvironment. Several TRAAC molecules are in discovery and clinical stages.
TAC-001:A lead immunostimulatory ADC program designed to potentiate cancer vaccine efficacy and rejuvenate immune responses. It is in Phase 1/2 clinical studies for advanced solid tumors.
Next Generation Therapies:Includes precise conjugation of therapeutic oligo payloads such as CpG oligonucleotides (TLR9 Agonist), antisense oligonucleotides, and siRNA, expanding beyond conventional toxin payloads.

Specialties

Antibody Drug Conjugates (ADCs) Toll-like Receptor Agonist Antibody Conjugates (TRAAC) Immunotherapy Cancer Treatment Oligonucleotide-based Therapies

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Debt
T: -
FT: Debt
A: 15000000
MR: -
FA: $15 million
FAN: 15000000
D: 2023-08-02
FD: 2023-08-02
1 investors
Debt Latest
2023-08-02
$15.0M
1 investor (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

H

Hong I. Wan

President, Chief Executive Officer and Co-founder

LinkedIn (Pro only)
C

Curtis C. Hecht

Chief Business Officer

LinkedIn (Pro only)
L

Laura QM Chow

Interim Chief Medical Officer

P

Pavel Strop

Vice President, Research

M

Mark Karbarz

Executive Director, Biologics Development

E

Emma Abellana

Senior Director, Finance

View 16 more team members with Pro

Unlock Full Team Directory

Recent News

Tallac Therapeutics, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~380 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro